Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients - Concepedia

Concepedia

Publication | Closed Access

Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients

87

Citations

10

References

2018

Year

Marius Ilié, Jonathan Juco, Lingkang Huang, Véronique Hofman, Shirin Khambata‐Ford, Paul Hofman

Cancer Cytopathology

Abstract

ASL48 and BenchMark Ultra 22C3 antibody concentrate-based LDTs have been validated for PD-L1 testing in cytology samples, and they will support reliable, high-quality PD-L1 testing across regions globally. Cancer Cytopathol 2018;126:264-74. © 2018 American Cancer Society.

References

	Year	Citations

Page 1